Fixing the Price of the Orphan Drug Siklos®: The Council of State Takes over the Decision

in European Journal of Health Law
Restricted Access
Get Access to Full Text
Rent on DeepDyve

Have an Access Token?



Enter your access token to activate and access content online.

Please login and go to your personal user account to enter your access token.



Help

Have Institutional Access?



Access content through your institution. Any other coaching guidance?



Connect

If the inline PDF is not rendering correctly, you can download the PDF file here.

Fixing the Price of the Orphan Drug Siklos®: The Council of State Takes over the Decision

in European Journal of Health Law

Sections

References

2

Haute Autorité de Santé 2005Recommandations pour la pratique clinique: Prise en charge de la drépanocytose chez l’enfant et l’adolescent. Retrieved 21 December 2013 www.has-sante.fr/portail/jcms/c.../drepanocytose-recommandationspdf.

4

On 9 July 2003the European Commission granted an orphan designation (EU/3/03/154) to Addmedica for hydroxycarbamid for the treatment of sickle cell syndrome within the eu: European Medicines Agency 2008 Committee for orphan medicinal products Pre-authorisation Evaluation of Medicines for Human Use public summary of positive opinion for orphan designation of hydroxyurea for the treatment of sickle cell syndrome. Retrieved 21 December 2013 http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500006488.pdf.

5

European Medicines Agency 2007European public assessment report (epar) for Siklos EMA/825511/2010. Retrieved 21 December 2013 www.ema.europa.eu/.../WC500050498.pdf.

6

Haute Autorité de Santé 2007Avis de la Commission de Transparence Siklos. Retrieved 24 December 2013 www.has-sante.fr/portail/jcms/c_627642/ct-5016.

11

On 26 September 2012the manufacturer called for the second time the Council of State to suspend the unilateral decision of the ceps to fix the price of the pharmaceutical drug. The Council of State rejected the stay the judge deciding that the application was moot because the price decision was already executed (already published in the official journal). ce 26 September 2012 n°361787. Available at: http://www.juricaf.org/arret/FRANCE-CONSEILDETAT-20120926-361787.

16

S. Murteira A. Millier and M. Toumi“Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: market access implications”Journal of Market Access & Health Policy 2 (2014) 22814.

24

NICE 2013Technology appraisal guidance 294 — Aflibercept solution for injection for treating wet age-related macular degeneration. Retrieved 10 January 2014 http://www.nice.org.uk/nicemedia/live/14227/64572/64572.pdf.

25

NICE 2013Technology appraisal guidance 283 — Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. Retrieved 10 January 2014 http://www.nice.org.uk/nicemedia/live/14169/63851/63851.pdf.

26

Ministère de la Santé 2012«Point sur l’utilisation de la spécialité Avastin® par voie intra oculaire [Press release]» 30-7-2012. Available at: http://www.sante.gouv.fr/point-sur-l-utilisation-de-la-specialite-avastin-r-par-voie-intra-oculaire.html.

Figures

  • View in gallery
    Timeline of the legal proceedings between the company Addmedica and French hta authorities regarding the reimbursement and pricing of the pharmaceutical drug Siklos®

Index Card

Content Metrics

Content Metrics

All Time Past Year Past 30 Days
Abstract Views 17 17 7
Full Text Views 2 2 2
PDF Downloads 0 0 0
EPUB Downloads 0 0 0